Key result
Despite significant pre-hospital and in-hospital treatment delays during the COVID-19 pandemic, the 6-month incidence of major adverse cardiac and cerebrovascular events following primary PCI for STEMI was comparable to the pre-pandemic period (14.6% vs 16.7%, p=0.514).
Why the study?
Little was known about the clinical characteristics and treatment outcomes of STEMI in Korea during the COVID-19 era.
Does primary percutaneous coronary intervention during the COVID-19 era affect major adverse cardiac and cerebrovascular events in patients with ST-segment elevation myocardial infarction compared to the pre-COVID-19 era?
Cohort (n=588)
No
Does primary percutaneous coronary intervention during the COVID-19 era affect major adverse cardiac and cerebrovascular events in patients with ST-segment elevation myocardial infarction compared to the pre-COVID-19 era?
Absolute Event Rate: 14.6% vs 16.7%
p-value: p=0.514
The COVID-19 pandemic was associated with significant pre-hospital and in-hospital treatment delays for STEMI patients, though short-term clinical outcomes remained largely comparable to the pre-pandemic era.
Treatment delays in STEMI during COVID-19 merit vigilance despite comparable short-term outcomes; extends observational data on pandemic effects.
BACKGROUND/AIMS: Little is known about the clinical characteristics and treatment outcomes of ST-segment elevation myocardial infarction (STEMI) in Korea during the coronavirus disease 2019 (COVID-19) era. We aimed to evaluate the clinical characteristics and treatment outcomes of patients with STEMI in the COVID-19 era. METHODS: A total of 588 consecutive patients with STEMI who underwent primary percutaneous coronary intervention were included in this study. The patients were categorized into the COVID-19 (from January 20, 2020 to December 31, 2020) and control groups (from January 20, 2019 to December 31, 2019). RESULTS: The COVID-19 group showed pre-hospital and in-hospital delays than the control group. The control group underwent more thrombus aspiration and had a higher proportion of left main coronary artery diseases, while the COVID-19 group had a higher proportion of multivessel diseases with a marked increase in the number and total length of stents than the control group. As for the prescribed medications, the COVID-19 group was administered more beta-blockers, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, and statins than the control group. The clinical outcomes were comparable between the groups, except for higher incidences of atrioventricular block and temporary pacemaker implantation in the COVID-19 group. CONCLUSION: Reperfusion after STEMI treatment during the COVID-19 period was delayed; therefore, efforts should be made to improve on reperfusion.
No takes yet. Share an insight, caveat, or question.
Oh et al. (2022) conducted a cohort in ST-segment elevation myocardial infarction (STEMI) (n=588). COVID-19 pandemic period vs. Pre-COVID-19 period was evaluated on Major adverse cardiac and cerebrovascular events (MACCEs) at 6 months (p=0.514). Despite significant pre-hospital and in-hospital treatment delays during the COVID-19 pandemic, the 6-month incidence of major adverse cardiac and cerebrovascular events following primary PCI for STEMI was comparable to the pre-pandemic period (14.6% vs 16.7%, p=0.514).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: